ECSP22007726A - RELAXIN ANALOGS AND METHODS OF USING THEM - Google Patents

RELAXIN ANALOGS AND METHODS OF USING THEM

Info

Publication number
ECSP22007726A
ECSP22007726A ECSENADI20227726A ECDI202207726A ECSP22007726A EC SP22007726 A ECSP22007726 A EC SP22007726A EC SENADI20227726 A ECSENADI20227726 A EC SENADI20227726A EC DI202207726 A ECDI202207726 A EC DI202207726A EC SP22007726 A ECSP22007726 A EC SP22007726A
Authority
EC
Ecuador
Prior art keywords
rln
analogs
disclosed
methods
relaxin
Prior art date
Application number
ECSENADI20227726A
Other languages
Spanish (es)
Inventor
Xiaojun Wang
Petra Verdino
Stacey Lynn Lee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22007726A publication Critical patent/ECSP22007726A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan análogos de relaxina (RLN) que incluyen modificaciones que aumentan la semivida en comparación con la RLN humana nativa, que mantienen la selectividad para el receptor RXFP1 y que proporcionan estabilidad in vitro e in vivo para mejorar las propiedades de farmacología y reducir la inmunogenicidad. También se divulgan composiciones farmacéuticas que incluyen uno o más de los análogos de RLN descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se divulgan métodos para elaborar y usar los análogos de RLN, en especial para tratar afecciones, enfermedades o trastornos cardiovasculares, pulmonares y/o renales.Relaxin (RLN) analogs are disclosed that include modifications that increase half-life compared to native human RLN, maintain selectivity for the RXFP1 receptor, and provide in vitro and in vivo stability to improve pharmacology properties and reduce immunogenicity. . Pharmaceutical compositions that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier are also disclosed. Also disclosed are methods of making and using the RLN analogs, especially to treat cardiovascular, pulmonary, and/or renal conditions, diseases, or disorders.

ECSENADI20227726A 2019-07-31 2022-01-31 RELAXIN ANALOGS AND METHODS OF USING THEM ECSP22007726A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962880968P 2019-07-31 2019-07-31
US202062970005P 2020-02-04 2020-02-04

Publications (1)

Publication Number Publication Date
ECSP22007726A true ECSP22007726A (en) 2022-02-25

Family

ID=72087312

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20227726A ECSP22007726A (en) 2019-07-31 2022-01-31 RELAXIN ANALOGS AND METHODS OF USING THEM

Country Status (18)

Country Link
US (2) US20220378931A1 (en)
EP (2) EP4004028A1 (en)
JP (3) JP7270105B2 (en)
KR (1) KR20220031044A (en)
CN (2) CN114174347A (en)
AU (1) AU2020321977C1 (en)
BR (1) BR112022001448A2 (en)
CA (2) CA3145491A1 (en)
CL (1) CL2022000178A1 (en)
CO (1) CO2022000656A2 (en)
CR (1) CR20220021A (en)
DO (1) DOP2022000018A (en)
EC (1) ECSP22007726A (en)
IL (1) IL289464A (en)
JO (1) JOP20220023A1 (en)
MX (1) MX2022001136A (en)
PE (1) PE20220965A1 (en)
WO (2) WO2021022139A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3551209T1 (en) 2016-12-09 2021-10-29 Akston Biosciences Corp Insulin-fc fusions and methods of use
BR112020014834A2 (en) * 2018-01-31 2020-12-08 Sanofi MODIFIED LIPID RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE
HRP20221418T1 (en) 2018-06-29 2023-01-06 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20231433T1 (en) 2019-12-19 2024-03-29 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3146464C (en) 2020-04-10 2024-03-12 Todd C. Zion Antigen specific immunotherapy employing covid-19 fusion proteins and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
PE20240233A1 (en) * 2021-02-02 2024-02-16 Lilly Co Eli FRACTIONS THAT PROLONG THE HALF-LIFE AND METHODS OF USE OF THESE
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
BR9407508A (en) 1993-09-17 1997-01-07 Novo Nordisk As Insulin derivative pharmaceutical composition and process for the treatment of diabetes in a patient in need of this treatment
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
ES2369895T3 (en) 2003-12-03 2011-12-07 Novo Nordisk A/S MONOCATENARY INSULIN.
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007104738A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US7888913B1 (en) 2009-09-08 2011-02-15 Intermec Ip Corp. Smart battery charger
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US20110250215A1 (en) 2010-04-02 2011-10-13 Athena Discovery, Inc. Structurally-related relaxin-fusion proteins with extended in vivo half-lives
CN103068842B (en) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 Insulin receptor INSR is had highly active single-chain insulin agonist
LT2605789T (en) 2010-08-17 2019-09-10 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9359422B2 (en) 2010-09-08 2016-06-07 The University Of Queensland Single chain relaxin polypeptides
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
MX2014000316A (en) 2011-07-08 2014-02-19 Bayer Ip Gmbh Fusion proteins releasing relaxin and uses thereof.
US20160152679A1 (en) 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
CN103509118B (en) 2012-06-15 2016-03-23 郭怀祖 insulin-Fc fusion protein
AR091902A1 (en) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
KR102163936B1 (en) 2012-11-05 2020-10-13 케이스 웨스턴 리저브 유니버시티 Long-acting single-chain insulin analogues
AR094147A1 (en) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft FUSION POLIPEPTIDES WITH RELAXIN ACTIVITY AND ITS USES
ES2868351T3 (en) * 2013-02-26 2021-10-21 Hanmi Pharm Ind Co Ltd Insulin Analog Conjugates and Uses Thereof
BR112016009572A2 (en) * 2013-11-07 2017-09-19 Shanghai hengrui pharmaceutical co ltd HUMAN RELAXIN ANALOG, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATIONS
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP3098235A4 (en) * 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
US10264071B2 (en) * 2014-03-31 2019-04-16 Amazon Technologies, Inc. Session management in distributed storage systems
US10081662B2 (en) 2014-04-17 2018-09-25 The Florey Institute Of Neuroscience And Mental Health Modified relaxin B chain peptides
JP6829928B2 (en) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ Biphasic single chain insulin analog
MA41794A (en) 2015-03-18 2018-01-23 The California Institute For Biomedical Res MODIFIED THERAPEUTIC AGENTS AND ASSOCIATED COMPOSITIONS
AR105616A1 (en) 2015-05-07 2017-10-25 Lilly Co Eli FUSION PROTEINS
AU2016315889A1 (en) * 2015-09-04 2018-03-22 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
WO2017052305A1 (en) 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Method of insulin production
WO2017100540A2 (en) * 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
JP7417421B2 (en) * 2016-12-07 2024-01-18 アブリンクス エン．ヴェー． Improved serum albumin-binding immunoglobulin single variable domain
CN110225924B (en) * 2017-01-25 2024-04-02 免疫医疗有限公司 Relaxin fusion polypeptides and uses thereof
BR112019016139A2 (en) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company modified relaxin polypeptide comprising a pharmacokinetic enhancer and uses thereof
UY37629A (en) 2017-03-07 2018-10-31 Univ Case Western Reserve SIMPLE CHAIN INSULIN ANALOGS STABILIZED BY A FOUR DISULFURED BRIDGE
JOP20190273A1 (en) 2017-05-26 2019-11-24 Lilly Co Eli Acylated insulin compound
KR20190036956A (en) * 2017-09-28 2019-04-05 한미약품 주식회사 A long acting single chain insulin analog and a conjugate thereof
US20210171598A1 (en) * 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans

Also Published As

Publication number Publication date
EP4004027A1 (en) 2022-06-01
JP2024009827A (en) 2024-01-23
JOP20220023A1 (en) 2023-01-30
IL289464A (en) 2022-02-01
TW202120536A (en) 2021-06-01
AU2020321977B2 (en) 2023-10-19
MX2022001136A (en) 2022-02-16
DOP2022000018A (en) 2022-03-15
JP2022542980A (en) 2022-10-07
WO2021022149A1 (en) 2021-02-04
AU2020321977C1 (en) 2024-04-18
CA3145491A1 (en) 2021-02-04
EP4004028A1 (en) 2022-06-01
CN114174347A (en) 2022-03-11
AU2020321977A1 (en) 2022-02-24
CR20220021A (en) 2022-02-11
CO2022000656A2 (en) 2022-01-28
BR112022001448A2 (en) 2022-05-17
CN114174348A (en) 2022-03-11
PE20220965A1 (en) 2022-06-10
US20220275042A1 (en) 2022-09-01
KR20220031044A (en) 2022-03-11
WO2021022139A1 (en) 2021-02-04
JP2022542301A (en) 2022-09-30
CA3144989A1 (en) 2021-02-04
CL2022000178A1 (en) 2022-11-18
JP7270105B2 (en) 2023-05-09
US20220378931A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
ECSP22007726A (en) RELAXIN ANALOGS AND METHODS OF USING THEM
ECSP21027049A (en) PROTEIN TYROSINE PHOSPHATASE INHIBITORS
CL2021001073A1 (en) Protein tyrosine-tyrosine analogs and methods of using it
ECSP17022931A (en) USE OF A LONG-ACTING GLP-1 / GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCHOLIC FATTY LIVER DISEASE
CL2021001430A1 (en) Glp-1 compositions and their uses. (request divisional 202000422)
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
CL2016003048A1 (en) Panonin analogues minimizes synthesis and use thereof.
UY35465A (en) NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET)
CL2019002297A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto.
CR20190208A (en) Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
AR103246A1 (en) DERIVATIVES OF FGF21 AND ITS USES
CO2020005919A2 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CO2021005915A2 (en) Stable compositions of semaglutide and uses thereof
CL2021003272A1 (en) Parenteral Pharmaceutical Composition of Dual Glp1/2 Agonist
BR112017004223A2 (en) method for inducing phycobiliprotein synthesis
DOP2020000192A (en) CONJUGATES OF THE PEPTIDE OF FUSION PEPTIDE SIMILAR TO GLUCAGON 1 (GLP-1) COUPLED TO THE PEPTIDE TYROSINE TYROSINE AND USES OF THESE
AR111236A1 (en) INTRADIALITICAL USE OF SODIUM TIOSULFATE
BR112022002491A2 (en) cbd formulations and uses thereof
AR119473A1 (en) RELAXIN ANALOGS AND METHODS OF USING THEM
PE20180658A1 (en) TOTAL SYNTHESIS OF SHISHIJIMICIN A AND ITS ANALOGUES
BR112018012030A2 (en) composition for reducing urination frequency, method of production and use thereof
CO2017007189A2 (en) Fumagillol derivatives
AR124616A1 (en) DEXTROMETADONE AS A DISEASE MODIFYING THERAPY FOR NEUROPSYCHIATRIC DISORDERS AND DISORDERS
AR114282A1 (en) PROTEIN SECRETION INHIBITORS BASED ON TRIAZACICLODODECANSULFONAMIDE ("TCD")
CO2020012484A2 (en) Triazacyclododecanesulfonamide ("tcd") based protein secretion inhibitors